Affiliations: [a] Central Laboratory Animal Facility (ZVTE), Johannes Gutenberg University Mainz, Mainz, Germany | [b] Department of Biochemistry, Johannes Gutenberg University Mainz, Mainz, Germany | [c] Department of Psychiatry and Psychotherapeutics, Johannes Gutenberg University Mainz, Mainz, Germany
Correspondence:
[*]
Corresponding authors: Dr. Anja Schroeder, Zentrale Versuchstiereinrichtung, Augustusplatz 14, 55099 Mainz, Germany. E-mail: [email protected]. Prof. Dr. Falk Fahrenholz, Institute of Biochemistry, University of Mainz, J.-J.-Becherweg 30, 55099 Mainz, Germany.
Note: [] Communicated by Thomas Bayer
Abstract: The α-secretase cleaves in the non-amyloidogenic pathway the amyloid-β protein precursor (AβPP) within the region of the amyloid-β peptides to prevent their formation and aggregation in the brain. Members of the ADAM family (a disintegrin and metalloprotease) are the main candidates for physiologically relevant α-secretases. We recently demonstrated that overexpression of ADAM10 in mice transgenic for human AβPP (ADAM10 x APP[V717I]) alleviated functional deficits related to Alzheimer's disease. To further demonstrate that this is due to the specific activity of α-secretase, we characterized mice overexpressing an inactive form of ADAM10 (ADAM10[E384A]; ADAM10-dn). Three lines of mice (controls (C57Bl/6 x FVB), APP[V717I] transgenics and ADAM10-dn x APP[V717I] double-transgenics) were investigated with respect to learning and memory in the Morris water maze. Double-transgenic mice overexpressing ADAM10-dn behaved similar to APP[V717I] overexpressing mice. This provides further evidence that ADAM10 in vivo by its enzymatic activity is able to counteract cognitive deficits. Stimulation of α-secretase activity might thus be a suitable approach to study treatment strategies of Alzheimer's disease.
